tbuckley/cabot-search huggingface dataset:
AB0832 The clinical profile of cases of inflammatory muscle disease in university of malaya medical centre (UMMC)
Authors: R. Jasmin, T.E. Cheah, K.J. Goh, D. Singh, S. Sockalingam
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Inflammatory muscle diseases commonly present with proximal myopathy. However, important differential diagnoses include muscular dystrophy and metabolic myopathy. <h3>Objectives</h3> To study the clinical profile of inflammatory muscle disease in our patients and to compare the clinical and histopathological diagnosis in these patients. <h3>Methods</h3> A retrospective study of 25 patients who presented to Rheumatology unit, UMMC from January 2007 to September 2011 with the clinical diagnosis of possible inflammatory myopathy was done. All had muscle biopsy done. <h3>Results</h3> Mean age was 53.3 years. Of the 25 patients, 17(68%) had diagnosis based on clinical presentation. 16(64%) had diagnosis based on muscle biopsy in which 9(36%) had the histopathological diagnosis of dermatomyositis, 3(12%)polymyositis, 2(8%)muscular dystrophy, 1(4%)inclusion body myositis (IBM) and 1(4%) metabolic myopathy. The remainder 9(36%) had inconclusive histopathological diagnosis. Significant correlation (<i>p</i>=0.01) was seen between clinical diagnosis and the histopathological diagnosis. Final diagnosis of dermatomyositis was made in 11(44%) patients, amyopathic dermatomyositis 2(8%), polymyositis 5(20%), Becker's muscular dystrophy 2(8%),MCTD 2(8%) and 1(4%) each for IBM, fibromyalgia, and metabolic myopathy. 19 patients had inflammatory myositis conclusively. The most common clinical presentation was proximal myopathy (23, 92%), followed by muscle pain (13, 52%). Raised serum creatinine kinase was seen in all patients and 21(84%) had transaminitis. 18(72%) had positive ANA titre. ENA was positive in 7(28%) out of which 4 were anti-Jo-1 positive. 88% received corticosteroids and 72% received immunosuppressive agents. 9(36%) attained clinical remission. <h3>Conclusions</h3> Diagnosis of muscular pathologies through muscle biopsies significantly correlated with our clinical diagnosis. Dermatomyositis is the prominent inflammatory muscle disease. <h3>References</h3> Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008 Feb 5;70(6):418-24. Karen R. Inflammatory myopathies: Narrowing the differential diagnosis. Cleveland Clinical Journal of Medicine. 2001 June;68 (6): 505-519 Erik AW, Robert LW. Diagnosis and management of inflammatory muscle disease. The J Musculoskel Med. 2010;27:470-479 <h3>Disclosure of Interest</h3> None Declared
Abstract 1163: Sensitive and specific detection of clinically relevant proteins in human testicular germ cell tumors using proximity ligation and quantitative PCR
Authors: Leendert H. Looijenga, Ad J. Gillis, Hans Stoop, Katharina Bierman, Elana Swartzman, Astrid Ferlinz, Wolter J. Oosterhuis, Mark Shannon
Journal: Cancer Research (2010)

Abstract Human testicular germ cell tumors (TGCTs) are the most frequent solid cancer in Caucasian males between the ages of 15 and 45 years. In spite of the high success rate of current treatment strategies (surgery, irradiation and chemotherapy), TGCTs are the second leading cause of death in this age group. The initiating event, leading to carcinoma in situ (CIS), occurs during embryonal development, offering a window of opportunity for early detection and intervention, thereby preventing the need for intensive (systemic) treatment. CIS is the malignant counterpart of a primordial germ cell, and can be effectively diagnosed using immunohistochemisty for OCT3/4, NANOG, c-KIT and its ligand (stem cell factor, SCF). In addition, SOX17 and SOX2 are informative for the diagnosis of the invasive components seminoma and embryonal carcinoma. Currently, in a clinical setting, these proteins are detected using predominantly immunohistochemistry, an approach that is labor-intensive and non-quantitative. Here we present data on the detection of these proteins using a novel qPCR-based method, Taqman Protein Expression Assay, which is based on the Proximity Ligation Assay (PLATM) technology. The method was first validated on negative controls and a series of TGCT-derived cell lines with efficient siRNA-induced down-regulation of the targets, an informative system for investigating stem cell regulatory circuits. Subsequently, the assay was further developed to enable analysis of both snap frozen and formalin-fixed paraffin-embedded (FFPE) tissues. The assays were found to be fast (results in less than 1 day), highly reproducible (SD less than 0.2 CTs), sensitive (able to detect target protein from as few as 10-100 cells, depending on the level of expression of the protein under investigation), and quantitative. Taqman Protein Expression Assays therefore allow the systematic analysis of multiple proteins within a single small sample in a high throughput set up, and offer unique opportunities for sensitive, specific and quantitative protein detection in both experimental and clinical studies. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1163.
SAT0157 Concurrent Use of Methotrexate and Celecoxib Increases Risk of Silent Liver Fibrosis in Rheumatoid Arthritis Patients with Reduced Kidney Function: Table 1.
Authors: J. Park, Y.-B. Park, S.-K. Lee, S.-W. Lee
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> We evaluated the effects of concurrent use of methotrexate and celecoxib on silent liver and kidney damages in rheumatoid arthritis (RA) patients. <h3>Methods</h3> We enrolled 92 RA patients with normal liver and kidney functions, who had received methotrexate and celecoxib concurrently over 6 months. Liver stiffness measurement (LSM) using transient elastography and ultrasonography were performed along with blood and urine tests. Estimated glomerular filtration rate (eGFR) was calculated by both CKD-EPI and MDRD equations. Initial eGFR was calculated with variables at the time of the initiation of celecoxib. The cutoff for abnormal LSM values was adopted as 5.3 kPa. The optimal cutoff of each eGFR for abnormal LSM values was also calculated. <h3>Results</h3> The median age (female: 80.4%) was 55 years. The median LSM was 4.4 kPa and the median eGFRs and initial eGFRs were mostly belonging to normal reference ranges. The cumulative doses of methotrexate and celecoxib and their concurrent administration duration did not affect LSM values and eGFRs. Among variables with significance, both eGFRs and initial eGFRs were significantly associated with LSM values. Patients with initial eGFR(CKD-EPI), initial eGFR(MDRD) and eGFR(CKD-EPI) below 66.5 mL/min/1.73m<sup>2</sup> , 59.5 mL/min/1.73m<sup>2</sup> , and 60 mL/min/1.73m<sup>2</sup> (RR 9.4, 10.3 and 4.4, p&lt;0.001, respectively) had significantly high risks of the potential of newly developed silent liver fibrosis, compared to those without (Table 1). <h3>Conclusions</h3> Reduced kidney function rather than the cumulative dose or concurrent administration duration could predict the development of silent liver fibrosis in RA patients who had received methotrexate and celecoxib concurrently for at least 6 months. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3581
922 INCREASED CANCER RISK IN A LARGE POPULATION-BASED COHORT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: FOLLOW-UP FOR UP TO 36 YEARS
Authors: K. Boonstra, P.H. Stadhouders, H.A.R.E. Tuynman, A.C. Poen, C.M.J. van Nieuwkerk, E.M. Witteman, D. Hamann, B.J. Witteman, U. Beuers, C.Y. Ponsioen
Journal: Journal of Hepatology (2013)
Abstract P3-08-01: The prospective risk of ovarian cancer in 1433 women in a breast cancer family history clinic: no increased risk in families testing negative for <i>BRCA1</i> and <i>BRCA2</i>.
Authors: DGR Evans, SL Ingham, S Sahin, I Buchan, J Warwick, C O'Hara, A Moran, A Howell
Journal: Cancer Research (2012)

Abstract Since the identification of the BRCA1 and BRCA2 genes speculation has continued regarding the breast and ovarian cancer risk associated with mutations in these genes. Also, as to whether mutations in these genes account for the majority of the association between breast and ovarian cancer. Identification of RAD51C and RAD51D mutations in breast/ovarian cancer families has reawakened the debate as to whether it is safe to reassure women from BRCA negative families that they are not at increased risk of ovarian cancer. 1433 women from breast cancer families that had tested negative for BRCA1/2 were followed for a total of between 0.04 and 25 years and checked against a cancer registry for ovarian cancer incidence. Data was censored at ovarian cancer diagnosis, oophorectomy or death. During 16358 women years of follow up no invasive epithelial ovarian cancer occurred, although 2 borderline tumors were diagnosed. Expected rates for this cohort from cancer registry data were 2.75 epithelial ovarian tumors with 2.52 for invasive cancer and 0.23 for borderline tumors. The upper confidence limit for invasive RR was 1.3 and for borderline tumors 0.97–31. In conclusion this the largest prospective follow up of a BRCA negative cohort has demonstrated that there is no increase in risk of invasive ovarian cancer in families that have tested negative for BRCA1/2. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-08-01.
PWE-166 Hepatic Artery Embolisation in Neuroendocrine Tumors; Outcomes From a Series of 50 Patients
Authors: M Pericleous, M Caplin, D Yu, L Morgan-Rowe, E Tsochatzis, C Toumpanakis
Journal: Gut (2013)

<h3>Introduction</h3> Transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are established treatments, mainly for symptom control, in patients with advanced NETs with predominantly hepatic tumour burden. The aim was to assess efficacy, toxicity, overall survival and predictive factors in patients undergoing TAE and TACE. <h3>Methods</h3> We carried out a retrospective analysis of 50 patients with NETs who underwent a total of 67 embolisation procedures in a period of nine years. All patients had either symptomatic and/or radiological progression despite previous treatments. <h3>Results</h3> The patients’ median age was 62 years (30 males/20 females). Thirty two had TAE and 19 had TACE. The majority of them had midgut (53%) followed by pancreatic NETs (27%). Symptomatic response was observed in 46 patients (69%), and radiological response (either disease stabilisation or partial response) in 51 (76%). There was no significant association between the type of procedure and symptomatic relief (p = 0.36) or radiological response rates (p = 0.23). Urinary 5HIAA and plasma CgA levels were reduced in 50% and 65% patients respectively, post procedures. Increase of plasma CgA levels post procedures was significantly associated with reduced OS (p = 0.0001). The median PFS for the whole group was 19.0 months (95% CI 13.2–24.8), whilst the median OS was 65.0 months (95% CI 22.7–107.3). High grade (G3) NETs were associated with significantly reduced OS (p = 0.002) and PFS (p = 0.043). There was no survival advantage on OS (p = 0.21) and PFS (p = 0.19) comparing TAE to TACE treatment. The presence of extra-hepatic metastases at the time of diagnosis was not associated with reduced survival (p = 0.72). Patients already on somatostatin analogues (38/50.76%), at the time of procedures, survived 46 months longer than those off analogues (p = 0.013), but somatostatin analogues did not affect PFS (p = 0.216). The commonest complication observed was post embolisation syndrome (22/50.44%), whilst mortality rate was 4%. Overall, the complication rate was not significantly different between TAE and TACE (p = 0.4). <h3>Conclusion</h3> TAE/TACE are beneficial treatments for control symptoms’ as well as tumour growth with acceptable morbidity and mortality rates. No significant efficacy and survival differences were shown between TAE and TACE. Extra-hepatic metastases at the time of treatment did not affect survival. Increase of plasma CgA levels, post-treatment, was associated with worse prognosis. The use of Somatostatin analogues at the time of treatment improved OS but not PFS. <b>Abbreviations</b> 5HIAA = 5-hydroxyindoleacetic acid, PFS = Progression-Free Survival, OS = Overall Survival, CgA = Chromogranin <h3>Disclosure of Interest</h3> None Declared.
Komen Foundation Recognizes Breast Cancer Scientists, Volunteers
Authors: D. Dortch
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Komen Foundation Recognizes Breast Cancer Scientists, Volunteers Get access Debbie Dortch Debbie Dortch Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 21, 1 November 1989, Pages 1611–1612, https://doi.org/10.1093/jnci/81.21.1611 Published: 01 November 1989
Abstract 843: Fast molecular response of marrow disease is highly prognostic in stage 4 neuroblastoma &amp;gt; 1 year
Authors: Janine Stutterheim, Lily Zappeij-Kannegieter, Rogier Versteeg, C. Ellen van der Schoot, Huib N. Caron, Godelieve A.M. Tytgat
Journal: Cancer Research (2010)

Abstract Aim Real-time quantitative (RQ)-PCR for detection of minimal residual disease (MRD) in children with neuroblastoma (NBL) can be used for evaluation of molecular bone marrow (BM) response. However its prognostic value still has to be established. We previously developed a panel of specific neuroblastoma RQ-PCR markers for MRD testing. The goal of this study was to determine whether sequential molecular assessment of BM using this panel of markers was prognostic for overall survival (OS). Methods In this single center study, RQ-PCR was performed with five NBL-specific markers: homeobox2b (PHOX2B), tyrosine hydroxylase (TH), dopamine decarbohydroxylase (DDC), growth associated protein 43 (GAP43) and cholinergic receptor3 (CHRNA3), on 106 retrospectively collected samples of 53 patients age &amp;gt; 1 year with metastatic disease. The prognostic impact of MRD at diagnosis (n=39), at 3 months after diagnosis (n=38) and after completing induction chemotherapy (n=29) was assessed using univariate and multivariate Cox regression analysis. Results At diagnosis, there was no correlation between tumor load in BM and outcome (Spearman's test, p=0.93). At 3 months after diagnosis, 29%(11/38) of the patients were in molecular BM remission, which was associated with favourable outcome (5-y-OS 62.3±15.0% versus 18.5±7.5%;p=0.009). After completion of induction chemotherapy, BM of 41%(12/29) of the patients was still MRD positive, which was associated with poor outcome (5-y-OS 0% versus 52.3±12,3;p&amp;lt;0.001). For both time points, the prognostic value of molecular response was an independent prognostic factor. Conclusion MRD detection measured by a panel of NBL specific-PCR targets could identify fast responders, who clear their BM early during treatment. Fast molecular response was an independent prognostic factor, associated with better outcome. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 843.
EARLY INITIATION OF EICOSAPENTAENOIC ACID AND STATIN TREATMENT IS ASSOCIATED WITH BETTER CLINICAL OUTCOMES THAN STATIN ALONE IN PATIENTS WITH ACUTE CORONARY SYNDROMES: 1-YEAR OUTCOMES OF A RANDOMIZED CONTROLLED STUDY
Authors: Kazumasa Nosaka, Toru Miyoshi, Keisuke Okawa, Saori Tsukuda, Masahiro Sogo, Tomoyuki Nishibe, Naoaki Mastuo, Masayuki Doi
Journal: Journal of the American College of Cardiology (2016)
Patients' Role in Accountable Care Organizations
Authors: Anna D. Sinaiko, Meredith B. Rosenthal
Journal: New England Journal of Medicine (2010)

An accountable care organization (ACO) model that does not attend to the way patients seek care may fail to achieve its cost-saving and quality goals and may give rise to a backlash. Policymakers should focus on creating incentives to build patients' loyalty to an ACO.
Reply from Authors re: Ansje S. Fortuin, Hanneke Meijer, Les C. Thompson, J. Alfred Witjes, Jelle O. Barentsz. Ferumoxtran-10 Ultrasmall Superparamagnetic Iron Oxide–Enhanced Diffusion-weighted Imaging Magnetic Resonance Imaging for Detection of Metastases in Normal-sized Lymph Nodes in Patients with Bladder and Prostate Cancer: Do We Enter the Era After Extended Pelvic Lymph Node Dissection? Eur Urol 2013;64:961–3
Authors: Frédéric D. Birkhäuser, Urs E. Studer, Harriet C. Thoeny
Journal: European Urology (2013)
Breast Cancer Treatment Successful Regardless of Age
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Breast Cancer Treatment Successful Regardless of Age Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 18, 16 September 1992, Page 1395, https://doi.org/10.1093/jnci/84.18.1395 Published: 16 September 1992
Abstract 2889: NF-κB inducing kinase modulates melanoma tumorigenesis by regulating pro-survival factors through β-catenin
Authors: Yee Mon Thu, Yingjun Su, Jinming Yang, Ryan Splittgerber, Ann Richmond
Journal: Cancer Research (2011)

Abstract Nuclear factor-κB (NF-κB) contributes to the progression of many cancers due to its role in regulating the transcription of genes important for inflammation, proliferation, apoptosis, and survival. In melanoma, high NF-κB activity results from constitutive elevation of IKKβ activity, a major kinase of this pathway. Targeted deletion of IKKβ prevents Ras induced melanoma tumor formation in INK4a/ARF-/- mice, underscoring the importance of NF-κB in melanoma. We have demonstrated that the NF-κB inducing kinase (NIK) is elevated in many melanoma cell lines. To determine the role of NIK overexpression in melanoma, we knocked down NIK using shRNA in WM115 and Hs294T human melanoma cell lines. NIK knock-down melanoma cells exhibited increased apoptosis and decreased proliferation. Similarly, NIK depletion substantially decreased tumor burden of WM115 cells in a xenograft model. Analysis of gene expression microarray data suggests that NIK modulates expression of c-Myc, c-Met, CCND2 and CXCR4, genes which are crucial for melanoma progression. Consistent with the apoptotic phenotype of NIK knock-down melanoma cells, expression of survival factors, such as Bcl2, cIAP1 and survivin, were attenuated in NIK knock-down melanoma cells. Intriguingly, Bcl2 and survivin expression levels (mRNA and protein) were also diminished in NIK knock-out mouse embryonic fibroblasts (MEFs), suggesting that these pro-survival genes are under the regulation of NIK. However, NF-κB activity is not reduced in NIK knock down cells, possibly due to the compensatory activation of IKKβ. Thus, we explored the possibility that NIK affects expression of survival factors in a NF-κB independent manner. Our data suggest that NIK regulates subcellular localization of β-catenin and modulates expression of survival genes such as survivin. Our findings reveal a novel mechanism by which NIK modulates pro-survival genes and suggest that NIK may be a promising therapeutic target for melanoma malignancy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2889. doi:10.1158/1538-7445.AM2011-2889
Acute intradialytic well-being: Results of a clinical trial comparing polysulfone with cuprophan
Authors: Giulio Mingardi, Stefano Rota, Rocco Misiani, Stefanla Bernareggi, Ornella Facci, Donatella Marchesi, Arrigo Schieppati, Lucto Gualandris, Giancarlo Orlandini, Luca Bonetti, Ariela Benigni, Antonella Piccinelli, Romana Licini, Aristide Mangili, Giuliano Mecca, Enza Poletti, Giacomo Tiraboschi, Claudio Grassi, Oscar Bracchi, Giovanni Pedroni, Agnese Meterange-Lis, Marco Lorenz, Patrizia Ondei, Luciano Pedrini, Giorgio Cozzi, Pietro Faranna, Mar-Cello Borghi, Giovanni Vendramin, Margherita Massazza, Luciano Rusconi, Patrizia Giuliano
Journal: Kidney International (1991)
Axillary recurrence (AR) after negative sentinel node biopsy (SNB): Who is at risk?
Authors: Rachel Leah Farkas, David G. Hicks, Ping Tang, Michelle Shayne, Alissa Huston, Marilyn N. Ling, Kristin A. Skinner
Journal: Journal of Clinical Oncology (2012)

180 Background: AR after negative SNB is a rare event. The purpose of this study was to identify factors associated with AR. Methods: A breast cancer (BC) database was reviewed identifying 4 cases of AR among 424 (0.9%) patients with a negative SNB over a 5 year period. Demographic, pathologic and treatment data were collected. Patients with AR were compared those without using standard methods for contingency tables to identify factors associated with AR. Results: Tumor and treatment factors are shown in the table. There was no difference in age, race, menopausal status, tumor size or palpability, or the average number of SLNs harvested between the groups. Recurrences were only seen in patients with triple negative (TN), high grade tumors. AR occurred in 12.5% of pN0(i+) BCs compared to 6% of pN0 BCs (p&lt;0.05). AR occurred in 3.5% of BCs with LVI compared to 0.5% of BCs without LVI (p&lt;0.05). AR occurred in 4.3% of high grade BCs compared to 0% of non-high grade BCs (p&lt;0.05). When comparing those with AR to TN patients without AR, patients with AR were less likely to have received chemotherapy(CT) (3 of the 4 patients declined). Both AR patients who received radiation therapy (XRT) had fields limited by anatomic constraints and the recurrence occurred outside of the radiated fields. AR occurred in 2% of TN BCs treated with CT compared to 19% of TN BCs not treated with CT (p&lt;0.05). Conclusions: For a patient to develop AR there must be retained occult disease in the axilla that is not controlled by adjuvant therapies given. Factors such as high grade tumors and LVI that increase the chances of node positivity or increase SNB false negative rates increase the chances of retained occult disease in the axilla. If these patients do not receive optimal adjuvant therapies, there is a substantial risk of AR. Care should be taken when using SNB in such high risk patients. [Table: see text]